Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALK IHC companion diagnostic - Roche Tissue Diagnostics

Drug Profile

ALK IHC companion diagnostic - Roche Tissue Diagnostics

Alternative Names: Alectinib companion diagnostic - Roche Tissue Diagnostics; ALK gene rearrangement diagnostic - Roche Tissue Diagnostics; Crizotinib companion diagnostic - Roche Tissue Diagnostics; RG 7853 companion diagnostic - Roche Tissue Diagnostics; VENTANA ALK (D5F3) CDx Assay; VENTANA ALK IHC diagnostic test

Latest Information Update: 27 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ventana Medical Systems
  • Developer Roche; Roche Tissue Diagnostics
  • Class Diagnostic agents; Monoclonal antibody diagnostics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 13 Jul 2021 Ventana Medical Systems is now called Roche Tissue Diagnostics
  • 09 Mar 2021 The US FDA approves the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic for ALK-positive Non-small cell lung cancer eligible for treatment with lorlatinib (Diagnosis) in USA
  • 01 Feb 2018 Preregistration for Non-small cell lung cancer (Diagnosis) in Japan (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top